dulaglutide

• Recruiting NCT NCT04731272

  GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

  Not yet reported University of Pennsylvania 30 participants Est. completion 2028-06-30 2 sites Stand-alone
  Other conditions: Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
  View official trial listing →
• Recruiting NCT NCT05390892

  PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

  Not yet reported Brigham and Women's Hospital 6000 participants Est. completion 2029-03-01 36 sites
  Cardiovascular disease Other conditions: Type2Diabetes
  View official trial listing →
• Recruiting NCT NCT05478707

  Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

  Not yet reported AdventHealth Translational Research Institute 47 participants Est. completion 2028-07-30 1 site
  Other conditions: Diabetes Mellitus, Type 1, Endothelial Dysfunction
  View official trial listing →
• Recruiting NCT NCT06324461

  GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery

  Not yet reported The University of Hong Kong 372 participants Est. completion 2028-12-31 3 sites Stand-alone
  Other conditions: Myocardial Injury
  View official trial listing →
• Recruiting NCT NCT06739122

  A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

  Not yet reported Eli Lilly and Company 55 participants Est. completion 2027-12 51 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Recruiting NCT NCT07109700

  A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin

  Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 216 participants Est. completion 2026-02-28 1 site
  Type 2 diabetes
  View official trial listing →
• Recruiting NCT NCT07282041

  Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

  Not yet reported, Not yet reported National University of Singapore 130 participants Est. completion 2030-12-01 1 site Stand-alone
  Cardiovascular disease Other conditions: Intracranial Atherosclerosis
  View official trial listing →
• Recruiting NCT NCT07309094

  Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

  Cardenal Herrera University 250 participants Est. completion 2028-12-31 1 site
  Chronic kidney diseaseType 2 diabetes Other conditions: Obesity
  View official trial listing →
• Recruiting NCT NCT07702461

  Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

  Ohio State University 300 participants Est. completion 2027-01 1 site
  Other conditions: Obesity & Overweight, Diabetes (DM)
  View official trial listing →
• Completed NCT NCT00630825

  A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 262 participants Est. completion 2009-01 34 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00734474

  A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

  Not yet reported, Not yet reported Eli Lilly and Company 1202 participants Est. completion 2012-07 99 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00791479

  Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 167 participants Est. completion 2010-01 46 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01001104

  A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 145 participants Est. completion 2010-12 6 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01064687

  A Study in Participants With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 978 participants Est. completion 2012-05 89 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01075282

  A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)

  Not yet reported Eli Lilly and Company 810 participants Est. completion 2012-11 78 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01126580

  A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

  Not yet reported Eli Lilly and Company 807 participants Est. completion 2012-06 91 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01149421

  A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

  Not yet reported Eli Lilly and Company 755 participants Est. completion 2012-01 76 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01191268

  A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

  Not yet reported Eli Lilly and Company 884 participants Est. completion 2012-09 101 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01215968

  A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 38 participants Est. completion 2011-07 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01250834

  LY2189265 and Atorvastatin Interaction Study

  Not yet reported Eli Lilly and Company 27 participants Est. completion 2011-03 1 site
  Other conditions: Healthy Volunteers
  View official trial listing →
• Completed NCT NCT01253304

  A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment

  Not yet reported Eli Lilly and Company 26 participants Est. completion 2011-11 2 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01300260

  Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

  Not yet reported Eli Lilly and Company 32 participants Est. completion 2011-08 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01301092

  A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

  Not yet reported Eli Lilly and Company 30 participants Est. completion 2011-08 1 site
  Other conditions: Diabetes Mellitus, Type II
  View official trial listing →
• Completed NCT NCT01324388

  A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

  Not yet reported Eli Lilly and Company 51 participants Est. completion 2011-08 3 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01394952

  Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

  Not yet reported Eli Lilly and Company 9901 participants Est. completion 2018-08-21 300 sites Stand-alone
  Cardiovascular diseaseType 2 diabetes
  View official trial listing →
• Completed NCT NCT01408888

  A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 29 participants Est. completion 2012-04 3 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01432938

  A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

  Not yet reported Eli Lilly and Company 28 participants Est. completion 2011-12 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01436201

  A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants

  Not yet reported Eli Lilly and Company 24 participants Est. completion 2011-11 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01458210

  A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants

  Not yet reported Eli Lilly and Company 22 participants Est. completion 2012-02 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01468181

  A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 394 participants Est. completion 2013-12 14 sites
  Type 2 diabetes
  View official trial listing →
• Enrolling by invitation NCT NCT01511393

  An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)

  Novo Nordisk A/S 6750 participants Est. completion 2039-12 1 site
  Type 2 diabetes Other conditions: Diabetes, Medullary Thyroid Carcinoma, Weight Management
  View official trial listing →
• Completed NCT NCT01524770

  A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe

  Not yet reported Eli Lilly and Company 50 participants Est. completion 2012-06 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01558271

  A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 492 participants Est. completion 2014-05 14 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01584232

  A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 361 participants Est. completion 2013-07 15 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01621178

  A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

  Not yet reported Eli Lilly and Company 577 participants Est. completion 2016-12 89 sites Stand-alone
  Type 2 diabetesChronic kidney disease
  View official trial listing →
• Completed NCT NCT01624259

  A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes

  Not yet reported Eli Lilly and Company 599 participants Est. completion 2013-11 57 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01644500

  A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 737 participants Est. completion 2014-08 30 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01648582

  A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 774 participants Est. completion 2014-12 30 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01667900

  A Study of Dulaglutide in Chinese Participants

  Not yet reported Eli Lilly and Company 58 participants Est. completion 2014-06 1 site Stand-alone
  Type 2 diabetes Other conditions: Healthy Volunteers
  View official trial listing →
• Completed NCT NCT01769378

  Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

  Not yet reported Eli Lilly and Company 300 participants Est. completion 2014-12 31 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02152371

  A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

  Not yet reported Eli Lilly and Company 300 participants Est. completion 2015-10 40 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02597049

  A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 424 participants Est. completion 2017-02 41 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02648204

  Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

  Not yet reported Novo Nordisk A/S 1201 participants Est. completion 2017-05-19 209 sites
  Type 2 diabetes Other conditions: Diabetes
  View official trial listing →
• Completed NCT NCT02750410

  A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 159 participants Est. completion 2018-06-18 25 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02759107

  A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

  Not yet reported Eli Lilly and Company 142 participants Est. completion 2017-06-26 2 sites
  Type 2 diabetes Other conditions: Healthy
  View official trial listing →
• Completed NCT NCT02770885

  Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)

  Not yet reported University Hospital, Basel, Switzerland 50 participants Est. completion 2019-10-07 1 site Stand-alone
  Other conditions: Primary Polydipsia
  View official trial listing →
• Completed NCT NCT02787551

  Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

  Not yet reported Sanofi 514 participants Est. completion 2018-11-17 124 sites Added to GLP-1
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02846233

  Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

  Not yet reported University of California, San Francisco 22 participants Est. completion 2018-12 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02963766

  A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 154 participants Est. completion 2022-01-12 61 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02973100

  A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

  Not yet reported Eli Lilly and Company 318 participants Est. completion 2017-08-14 66 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03015220

  Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

  Not yet reported Novo Nordisk A/S 458 participants Est. completion 2018-07-12 34 sites
  Type 2 diabetes Other conditions: Diabetes
  View official trial listing →
• Completed NCT NCT03131687

  A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 318 participants Est. completion 2018-08-01 49 sites Added to GLP-1
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03141632

  Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake

  Not yet reported University Hospital, Basel, Switzerland 17 participants Est. completion 2017-05-12 1 site
  Other conditions: Thirst, Water-Electrolyte Imbalance
  View official trial listing →
• Completed NCT NCT03204396

  Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues

  Not yet reported University Hospital, Basel, Switzerland 256 participants Est. completion 2022-08-30 1 site
  Other conditions: Glucagon-like Peptide-1, Smoking Cessation, Weight Change, Body, Craving
  View official trial listing →
• Completed NCT NCT03315780

  A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 12 participants Est. completion 2018-02-28 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03363906

  A Study of Dulaglutide in Healthy Participants

  Not yet reported Eli Lilly and Company 27 participants Est. completion 2018-06-06 1 site Stand-alone
  Other conditions: Healthy
  View official trial listing →
• Status unknown NCT NCT03444142

  Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes

  Not yet reported University of Guadalajara 30 participants Est. completion 2021-11-30 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03492580

  A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

  Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 site
  Type 2 diabetesCardiovascular disease
  View official trial listing →
• Completed NCT NCT03495102

  A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 1842 participants Est. completion 2019-10-10 208 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03498001

  Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging

  Not yet reported Centre Hospitalier Universitaire Dijon 42 participants Est. completion 2023-12-20 1 site Stand-alone
  Other conditions: Type II Diabetes
  View official trial listing →
• Completed NCT NCT03590626

  Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

  Not yet reported Medanta, The Medicity, India 60 participants Est. completion 2020-02-18 1 site Stand-alone
  Type 2 diabetes Other conditions: Non Alcoholic Fatty Liver Disease
  View official trial listing →
• Status unknown NCT NCT03648554

  Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)

  Not yet reported Central Hospital, Nancy, France 93 participants Est. completion 2024-03-30 9 sites Stand-alone
  Type 2 diabetesMASH
  View official trial listing →
• Completed NCT NCT03668470

  Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes

  Not yet reported Hospices Civils de Lyon 45 participants Est. completion 2021-02-03 7 sites Stand-alone
  Other conditions: Adult Subjects With Type1Diabetes and Insulin Microsecretion
  View official trial listing →
• Terminated NCT NCT03684642

  Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

  Not yet reported Sanofi 908 participants Est. completion 2020-11-17 45 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03724981

  A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

  Not yet reported Eli Lilly and Company 312 participants Est. completion 2019-04-12 14 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Terminated NCT NCT03743025

  Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

  Not yet reported Emory University 28 participants Est. completion 2023-05-02 3 sites Stand-alone
  Other conditions: Stress Hyperglycemia
  View official trial listing →
• Completed NCT NCT03824002

  Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

  Not yet reported University of Palermo 92 participants Est. completion 2018-04-20 1 site Stand-alone
  Other conditions: Diabetes Mellitus
  View official trial listing →
• Completed NCT NCT03861052

  A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 636 participants Est. completion 2021-03-31 46 sites
  Type 2 diabetes
  View official trial listing →
• Status unknown NCT NCT03959865

  GLP-1 REceptor Agonists and Real World EvIdeNce

  University of Padova 6000 participants Est. completion 2019-05-31 6 sites
  Type 2 diabetes
  View official trial listing →
• Status unknown NCT NCT03962010

  A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus

  Not yet reported Genexine, Inc. 78 participants Est. completion 2022-07-01
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04143802

  A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

  Not yet reported Eli Lilly and Company 72 participants Est. completion 2020-12-28 4 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04184947

  Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

  University of Padova 10000 participants Est. completion 2020-02-29 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04189848

  Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

  Not yet reported Novo Nordisk A/S 104 participants Est. completion 2020-02-27 1 site Added to GLP-1
  Type 2 diabetes Other conditions: Healthy Volunteers, Overweight, Obesity
  View official trial listing →
• Completed NCT NCT04200625

  Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

  University of Miami 80 participants Est. completion 2019-12-09 1 site
  Other conditions: Epicardial Fat
  View official trial listing →
• Completed NCT NCT04255433

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 13299 participants Est. completion 2025-06-12 635 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04374578

  Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes

  Shanghai Zhongshan Hospital 100 participants Est. completion 2021-06-30 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04387201

  GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

  Not yet reported The University of Texas Health Science Center, Houston 23 participants Est. completion 2023-10-06 1 site Stand-alone
  Other conditions: Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
  View official trial listing →
• Completed NCT NCT04466904

  Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

  Not yet reported, Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 42 participants Est. completion 2021-05-28 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04515576

  A Study of LY3493269 in Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 56 participants Est. completion 2021-03-09 3 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04591626

  A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 291 participants Est. completion 2022-04-28 27 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04641312

  A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 67 participants Est. completion 2021-12-21 2 sites Stand-alone
  Type 2 diabetes Other conditions: Healthy
  View official trial listing →
• Completed NCT NCT04687514

  Effects of Glucagon-Like Peptide-1 Analogs on Sexuality

  Not yet reported University Hospital, Basel, Switzerland 26 participants Est. completion 2022-09-05 1 site Stand-alone
  Other conditions: Sexual Functioning
  View official trial listing →
• Completed NCT NCT04809220

  A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 591 participants Est. completion 2023-04-26 44 sites Stand-alone
  Type 2 diabetes Other conditions: Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Hypoglycemic Agents
  View official trial listing →
• Completed NCT NCT04829903

  Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin

  Not yet reported Corporacion Parc Tauli 116 participants Est. completion 2021-11-20 1 site
  Type 2 diabetes Other conditions: Obesity, Adolescent Obesity
  View official trial listing →
• Terminated NCT NCT04862234

  Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients

  Not yet reported Emory University 16 participants Est. completion 2023-06-22 2 sites Stand-alone
  Other conditions: Hyperglycemia Stress
  View official trial listing →
• Completed NCT NCT04867785

  A Study of LY3437943 in Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 281 participants Est. completion 2022-10-27 43 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04876027

  GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)

  Not yet reported Shanghai 10th People's Hospital 68 participants Est. completion 2022-05-10 1 site
  Other conditions: Polycystic Ovary Syndrome
  View official trial listing →
• Status unknown NCT NCT04893148

  Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

  Not yet reported Chungbuk National University Hospital 40 participants Est. completion 2022-12-30 1 site
  Type 2 diabetes Other conditions: Glucose, High Blood
  View official trial listing →
• Completed NCT NCT04965506

  A Study of IBI362 in Chinese Patients With Type 2 Diabetes

  Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 252 participants Est. completion 2022-06-11 1 site
  Type 2 diabetes
  View official trial listing →
• Status unknown NCT NCT05005741

  The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

  Not yet reported Second Xiangya Hospital of Central South University 120 participants Est. completion 2023-12-31 4 sites
  Type 2 diabetes Other conditions: Overweight or Obesity
  View official trial listing →
• Completed NCT NCT05048719

  A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 383 participants Est. completion 2022-09-30 44 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05136287

  SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

  Jose Seijas Amigo 140 participants Est. completion 2024-01-01 11 sites
  Type 2 diabetes Other conditions: Weight Loss, Quality of Life, Safety Issues
  View official trial listing →
• Status unknown NCT NCT05140694

  Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

  Not yet reported Seoul National University Bundang Hospital 135 participants Est. completion 2025-12-31 Stand-alone
  Type 2 diabetes Other conditions: Metabolic-associated Fatty Liver Disease
  View official trial listing →
• Status unknown NCT NCT05161429

  BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

  Brigham and Women's Hospital 550000 participants Est. completion 2024-06-30 5 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05218915

  Basal Plus GLP1-ra on Glycemic Variability in CKD

  Not yet reported Elaine Chow 95 participants Est. completion 2024-10-30 1 site Stand-alone
  Chronic kidney disease Other conditions: Diabetes Mellitus
  View official trial listing →
• Active, not recruiting NCT NCT05220917

  Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

  Brigham and Women's Hospital 781430 participants Est. completion 2027-09-30 1 site
  Type 2 diabetes Other conditions: Cardiovascular Events, Renal Disease
  View official trial listing →
• Completed NCT NCT05254418

  Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease

  Not yet reported Vanderbilt University Medical Center 7 participants Est. completion 2024-08-01 1 site Stand-alone
  Chronic kidney disease
  View official trial listing →
• Status unknown NCT NCT05348122

  A Study of TG103 Injection in Type 2 Diabetes Subjects

  Not yet reported CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. 240 participants Est. completion 2023-11-01 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05377333

  A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 94 participants Est. completion 2023-11-22 5 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05407961

  A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 90 participants Est. completion 2024-01-12 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05459285

  A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects

  Not yet reported Sunshine Lake Pharma Co., Ltd. 68 participants Est. completion 2022-07-08 1 site
  Type 2 diabetes
  View official trial listing →
• Status unknown NCT NCT05492305

  Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health

  King's College London 20 participants Est. completion 2023-08 1 site
  Other conditions: Diabetes Mellitus, Obesity, Mental Health Issue
  View official trial listing →
• Completed NCT NCT05516966

  Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus

  Not yet reported Fujian Shengdi Pharmaceutical Co., Ltd. 64 participants Est. completion 2023-05-24 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05564039

  A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

  Not yet reported Eli Lilly and Company 282 participants Est. completion 2024-08-12 38 sites Added to GLP-1
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05606913

  A Study of IBI362 in Participants With Type 2 Diabetes

  Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 731 participants Est. completion 2024-04-09 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05659537

  A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India

  Not yet reported Eli Lilly and Company 212 participants Est. completion 2024-01-16 7 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05680129

  A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

  Not yet reported Hangzhou Sciwind Biosciences Co., Ltd. 623 participants Est. completion 2024-10-12 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05946148

  Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

  National and Kapodistrian University of Athens 78 participants Est. completion 2021-05-31 1 site
  Other conditions: Non-Alcoholic Fatty Liver Disease, Liver Steatosis
  View official trial listing →
• Status unknown NCT NCT05990374

  Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

  Not yet reported Nanjing First Hospital, Nanjing Medical University 100 participants Est. completion 2024-01-01 1 site
  Other conditions: Diabetes
  View official trial listing →
• Completed NCT NCT06120556

  Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

  Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari 130 participants Est. completion 2023-10-31 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT06148649

  Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

  Not yet reported Dongguan HEC Biopharmaceutical R&D Co., Ltd. 234 participants Est. completion 2025-04-23 2 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT06182891

  Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

  Not yet reported The Affiliated Hospital of Xuzhou Medical University 300 participants Est. completion 2023-10-30 1 site Stand-alone
  Chronic kidney disease
  View official trial listing →
• Completed NCT NCT06235086

  A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus

  Not yet reported CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. 632 participants Est. completion 2026-02-03 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Active, not recruiting NCT NCT06257966

  A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

  Not yet reported Beijing Dongfang Biotech Co., Ltd. 600 participants Est. completion 2026-11-30 1 site
  Type 2 diabetes
  View official trial listing →
• Status unknown NCT NCT06331286

  The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity

  Not yet reported First Affiliated Hospital of Zhejiang University 60 participants Est. completion 2024-12-31 1 site Stand-alone
  Other conditions: Bipolar Disorder, Obesity, Cognition
  View official trial listing →
• Status unknown NCT NCT06449235

  Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

  Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 site
  Other conditions: Type2diabetes
  View official trial listing →
• Completed NCT NCT06500143

  Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery

  Ciusss de L'Est de l'Île de Montréal 94 participants Est. completion 2025-02-28 1 site
  Other conditions: Gastric Retention
  View official trial listing →
• Completed NCT NCT06533527

  Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

  Not yet reported The Cleveland Clinic 69 participants Est. completion 2025-05-20 2 sites
  Type 2 diabetes Other conditions: Obesity, Gastroparesis
  View official trial listing →
• Enrolling by invitation NCT NCT06581120

  GLP_1 RA Ultrasound Study

  Children's Hospital Medical Center, Cincinnati 100 participants Est. completion 2026-07 1 site
  Other conditions: Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
  View official trial listing →
• Active, not recruiting NCT NCT06611904

  The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

  Not yet reported Attikon Hospital 60 participants Est. completion 2024-12-15 1 site
  Other conditions: Urine Albumin (UAlb), Glycocalyx, Arterial Stiffness
  View official trial listing →
• Completed NCT NCT06779929

  Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  Brigham and Women's Hospital 70000 participants Est. completion 2026-03-01 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT06851962

  Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

  Not yet reported Fundación para la Investigación del Hospital Clínico de Valencia 92 participants Est. completion 2026-06-30 3 sites Added to GLP-1
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT06901648

  A Study of HS-20094 in Patients With T2DM

  Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 275 participants Est. completion 2025-04-09 1 site
  Type 2 diabetes
  View official trial listing →
• Not yet recruiting NCT NCT07027969

  Metabolic Surgery for Atrial Fibrillation Elimination

  Not yet reported Ali Aminian 100 participants Est. completion 2030-03-31 1 site
  Other conditions: Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
  View official trial listing →
• Completed NCT NCT07088718

  Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

  Brigham and Women's Hospital 44671 participants Est. completion 2025-07-30 1 site
  Type 2 diabetes Other conditions: Major Adverse Cardiac Events, Cardiovascular (CV) Risk
  View official trial listing →
• Completed NCT NCT07096063

  Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

  Brigham and Women's Hospital 887132 participants Est. completion 2025-07-15 1 site
  Type 2 diabetes Other conditions: Overweight, Cardiovascular (CV) Risk
  View official trial listing →
• Not yet recruiting NCT NCT07156539

  A Phase 3 Study of HS-20094 in Patients With T2DM

  Not yet reported Jiangsu Hansoh Pharmaceutical Co., Ltd. 546 participants Est. completion 2027-05-30 2 sites
  Type 2 diabetes
  View official trial listing →
• Active, not recruiting NCT NCT07188545

  Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

  Ohio State University 23280000 participants Est. completion 2029-06-30 1 site
  Metabolic syndrome
  View official trial listing →
• Not yet recruiting NCT NCT07276763

  Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention

  Fudan University 16509 participants Est. completion 2025-12-15 1 site
  Other conditions: Gastric Retention
  View official trial listing →
• Completed NCT NCT07313813

  A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus

  Not yet reported Eli Lilly and Company 20 participants Est. completion 2026-08-13 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Enrolling by invitation NCT NCT07319286

  Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus

  Not yet reported, Not yet reported Ain Shams University 50 participants Est. completion 2027-03 2 sites
  Other conditions: Menstrual Irregularities, Type1 Diabetes Mellitus, Glucagon-Like Peptide-1 Receptor Agonists, Female Reproductive Health
  View official trial listing →
• Active, not recruiting NCT NCT07325435

  Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

  Not yet reported MaryAnn Banerji 60 participants Est. completion 2028-06-30 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT07370922

  Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia

  Not yet reported Ain Shams University 80 participants Est. completion 2026-01-05 1 site Stand-alone
  Other conditions: Transfusion Dependent Beta Thalassemia
  View official trial listing →
• Completed NCT NCT07417618

  INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

  Brigham and Women's Hospital 60000 participants Est. completion 2026-06-19 1 site
  Type 2 diabetesCardiovascular disease Other conditions: Overweight
  View official trial listing →
• Completed NCT NCT07417631

  Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.

  Brigham and Women's Hospital 300000 participants Est. completion 2026-06-15 1 site
  Type 2 diabetes
  View official trial listing →
• Not yet recruiting NCT NCT07537088

  Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

  Not yet reported First Affiliated Hospital of Wannan Medical College 468 participants Est. completion 2027-07 Stand-alone
  Type 2 diabetesChronic kidney disease
  View official trial listing →
• Completed NCT NCT07619495

  Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk

  Brigham and Women's Hospital 120000 participants Est. completion 2026-06-01 1 site
  Type 2 diabetes Other conditions: Obesity, Overweight
  View official trial listing →
• Not yet recruiting NCT NCT07668336

  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  Not yet reported Eli Lilly and Company 170 participants Est. completion 2030-03 71 sites
  Type 2 diabetes
  View official trial listing →
• Not yet recruiting NCT NCT07677891

  Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

  Not yet reported ProGen. Co., Ltd. 60 participants Est. completion 2027-06
  Type 2 diabetes
  View official trial listing →
• Not yet recruiting NCT NCT07787936

  GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry

  Miedziowe Centrum Zdrowia SA 150 participants Est. completion 2033-01-01 1 site
  Heart failure Other conditions: Obesity, Pulmonary Hypertension, Iron Deficiency
  View official trial listing →

Not yet reported.

Not yet reported.

• ClinicalTrials.gov — NCT01432938

No related coverage yet.